Corvus Pharmaceuticals Inc’s recent filing unveils that its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on Jun 27 ’25. In the deal valued at $4.16 per share,1,176,332 shares were sold. As a result of this transaction, ORBIMED ADVISORS LLC now holds 7,165,006 shares worth roughly $32.24 million.
Then, Thompson Peter A. sold 1,176,332 shares, generating $4,891,894 in total proceeds. Upon selling the shares at $4.16, the Director now owns 7,165,006 shares.
H.C. Wainwright initiated its Corvus Pharmaceuticals Inc [CRVS] rating to a Buy in a research note published on January 02, 2025; the price target was $11. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid August with a ‘”an Outperform”‘ rating. Cantor Fitzgerald started covering the stock on May 27, 2021. It rated CRVS as “an Overweight”.
Price Performance Review of CRVS
On Tuesday, Corvus Pharmaceuticals Inc [NASDAQ:CRVS] saw its stock jump 2.97% to $4.5. Over the last five days, the stock has gained 4.90%. Corvus Pharmaceuticals Inc shares have risen nearly 25.35% since the year began. Nevertheless, the stocks have fallen -15.89% over the past one year. While a 52-week high of $10.00 was reached on 01/06/25, a 52-week low of $2.54 was recorded on 04/09/25.
Levels Of Support And Resistance For CRVS Stock
The 24-hour chart illustrates a support level at 4.40, which if violated will result in even more drops to 4.30. On the upside, there is a resistance level at 4.58. A further resistance level may holdings at 4.65.
How much short interest is there in Corvus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Corvus Pharmaceuticals Inc stocks on 2025-07-31, dropping by -0.11 million shares to a total of 8.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 8.9 million shares. There was a decline of -1.27%, which implies that there is a negative sentiment for the stock.
